Company / Shareholders' Equity
NeoGenomics Laboratories, Inc. Shareholders' Equity History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$836.6M
FY2025
5-year range
$836.6M / $1.1B
FY2021-FY2025
Trend
-7.3%
vs FY2024
Sector context
#90 of 161
Health Care
What the data says
At $837M, NeoGenomics Laboratories, Inc.'s shareholders' equity ranks #90 of 161 in the Health Care sector. Shareholders' Equity has declined for 4 consecutive years, from $1.1B in FY2021 to $837M in FY2025.
Based on SEC 10-K filings.
$837M in FY2025 with a 5-year CAGR of +3.8%.
Declined from $942M to $837M over the past 2 years.
Health Care sector context is included.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- -5.7%
- 5-Year CAGR
- +3.8%
- 10-Year CAGR
- -
Sector benchmark
#90 of 161 in Health CareTop 56% of 161This company $836.6M Sector average $5.1B
▼
-83.5% below sector average
Key checks
Key Insights
- NeoGenomics Laboratories, Inc.'s shareholders' equity has declined for 4 consecutive years.
- 5-year CAGR of +3.8%, indicating consistent growth.
- In FY2025, shareholders' equity decreased 7.3% year-over-year.
- Ranks #90 out of 161 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 0.56 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $836.6M | -7.3% |
| FY2024 | $902.3M | -4.2% |
| FY2023 | $941.5M | -5.7% |
| FY2022 | $998.0M | -9.9% |
| FY2021 | $1.1B | +59.6% |
| FY2020 | $694.3M | +36.8% |
| FY2019 | $507.4M | +58.3% |
| FY2018 | $320.4M | +86.3% |
| FY2017 | $172.0M | +5.9% |
| FY2016 | $162.3M | -22.2% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026